The following post comes from Yumi Oda, an LLM Candidate at Scalia Law and a Research Assistant at CPIP.

By Yumi Oda

Many believe that drug prices in the U.S. are unnecessarily high because the pharmaceutical industry is exploiting legal loopholes and acquiring dubious patents to extend protection and delay generics from entering the market (so-called “evergreening” behavior by drug innovators). Read more